Biotech can’t continue to innovate under strain of Big Pharma market pressures

Biotech can't continue to innovate under strain of Big Pharma market pressures according to a May 19, 2026 opinion piece in BioSpace, which argues biotech is increasingly financed, governed, and regulated as if it were a mature pharma industry, despite lacking the same revenue base and facing the same political and pricing risks.

Capital has tightened sharply, forcing promising science to be delayed or abandoned as big pharma faces pressure from the Inflation Reduction Act, a looming patent cliff, and shifting global trade and pricing policies, which are squeezing margins and R&D models across the entire biopharma value chain.

The distinction between discovery‑stage biotech and commercial pharma has collapsed, leaving biotechs with higher risk, less upfront cash in licensing deals, and fewer stable capital markets, which threatens the sector’s long‑term innovation capacity unless structural reforms align capital, public investment, and policy with long‑cycle discovery.